These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 2569825)

  • 41. Effects of doxazosin on diet-induced hypercholesterolemia in C57BR/cdJ mice.
    Swindell AC; Valentine JJ
    Am J Cardiol; 1987 May; 59(14):29G-34G. PubMed ID: 2884850
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
    Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Doxazosin and atenolol as monotherapy in mild and moderate hypertension: a randomized, parallel study with a three-year follow-up.
    Talseth T; Westlie L; Daae L
    Am Heart J; 1991 Jan; 121(1 Pt 2):280-5. PubMed ID: 1824651
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Doxazosin therapy in the treatment of diabetic hypertension.
    Feher MD
    Am Heart J; 1991 Apr; 121(4 Pt 2):1294-301. PubMed ID: 1826186
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of doxazosin in the treatment of patients with mild or moderate essential hypertension and elevated levels of cholesterol.
    Taylor SH
    Am Heart J; 1991 Jan; 121(1 Pt 2):362-6. PubMed ID: 1824662
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of adrenoreceptor antagonists and agonists on clearance of emulsion models of triacylglycerol-rich lipoproteins from plasma in rats.
    Mackintosh VS; Elsegood CL; Redgrave TG
    Clin Exp Pharmacol Physiol; 1991 Nov; 18(11):775-88. PubMed ID: 1685947
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of alpha- and beta-blocker therapy on blood lipids: European experience.
    Leren P
    Am J Med; 1984 Feb; 76(2A):67-71. PubMed ID: 6142644
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of a new alpha 1-blocker, bunazosin hydrochloride, on plasma lipid components in hypertensive patients with hypercholesterolemia.
    Yashiro A; Sugano M; Nakashima Y; Tasaki H; Kuroiwa A
    Clin Ther; 1987; 10(1):98-106. PubMed ID: 2897239
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacotherapeutic stature of doxazosin and its role in coronary risk reduction.
    Taylor SH
    Am Heart J; 1988 Dec; 116(6 Pt 2):1735-47. PubMed ID: 2904744
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Alpha-blocker therapy; a possible advance in the treatment of diabetic hypertension--results of a cross-over study of doxazosin and atenolol monotherapy in hypertensive non-insulin dependent diabetic subjects.
    Feher MD; Henderson AD; Wadsworth J; Poulter C; Gelding S; Richmond W; Sever PS; Elkeles RS
    J Hum Hypertens; 1990 Oct; 4(5):571-7. PubMed ID: 1980930
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhibition of hepatic cholesterol synthesis by the alpha 1-adrenoceptor blocker doxazosin in the hypercholesterolemic golden hamster.
    Jansen H; Lammers R; Baggen MG; Penders JM; Birkenhäger JC
    Life Sci; 1989; 44(15):1013-7. PubMed ID: 2564614
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A double-blind parallel trial to assess the efficacy of doxazosin, atenolol and placebo in patients with mild to moderate systemic hypertension.
    Nash DT; Schonfeld G; Reeves RL; Black H; Weidler DJ
    Am J Cardiol; 1987 May; 59(14):87G-90G. PubMed ID: 2884859
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia.
    Fulton B; Wagstaff AJ; Sorkin EM
    Drugs; 1995 Feb; 49(2):295-320. PubMed ID: 7537194
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A single-blind study of doxazosin in the treatment of mild-to-moderate essential hypertensive patients with concomitant noninsulin-dependent diabetes mellitus.
    Castrignano R; D'Angelo A; Pati T; Al Awady M; Tronca R; Crepaldi G
    Am Heart J; 1988 Dec; 116(6 Pt 2):1778-84. PubMed ID: 2904750
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The cost-benefit approach to pricing new medicines: doxazosin versus beta-blocker treatment in Sweden.
    Lindgren B
    Am Heart J; 1990 Mar; 119(3 Pt 2):748-53. PubMed ID: 1968701
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effects of beta-adrenergic blocking agents on blood lipid levels.
    Wolinsky H
    Clin Cardiol; 1987 Oct; 10(10):561-6. PubMed ID: 2889552
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The antihypertensive effects of doxazosin: a clinical overview.
    Cox DA; Leader JP; Milson JA; Singleton W
    Br J Clin Pharmacol; 1986; 21 Suppl 1(Suppl 1):83S-90S. PubMed ID: 2939872
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Control of coronary heart disease risk factors with doxazosin as monotherapy and in combination therapy.
    Rosenthal J
    Am Heart J; 1988 Dec; 116(6 Pt 2):1763-6. PubMed ID: 2904747
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serum lipoproteins during treatment with antihypertensive drugs.
    Weidmann P; de Courten M; Ferrari P; Böhlen L
    J Cardiovasc Pharmacol; 1993; 22 Suppl 6():S98-105. PubMed ID: 7508069
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of doxazosin in mild to moderate hypertensive patients with insulin-dependent diabetes mellitus.
    Calò L; Davis PA; Cantaro S; Bonfante L; Castrignano R; Carraro G; D'Angelo A
    Acta Diabetol; 1998 Jul; 35(2):96-100. PubMed ID: 9747962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.